Sanofi India quarterly results

Q2 FY27 · Jul–Sep 2026

₹ crore	Q2 FY27	Q2 FY26	Change
Revenue	492	475	+3.4%
EBITDA	161	134	+20.1%
EBITDA margin	32.8%	28.2%	+4.6 pts
Profit before tax	158	102	+54.2%
Net profit	117	76.0	+53.6%
EPS	₹50.67	₹32.99	+53.6%

Every quarter

₹ crore except per share

Tap a line for its trend	Q2 FY27Sep 2026	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Earlier quartersAlpha Plus

Expenses
	492	438	472	420	475	406	536	515	524	464	732	694	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	5.5	6.2	4.4	2.8	4.9	8.7	3.3	5.9	2.3	4.8	6.5	12.0
	497	444	477	423	480	415	539	521	526	468	739	706
	73.6	57.3	50.3	55.3	53.3	62.1	75.7	103	93.1	82.1	144	134
	227	159	148	125	270	35.6	84.1	239	202	92.5	40.8	135
	−63.0	9.0	35.8	28.3	−83.2	111	80.7	−91.4	−34.9	46.5	124	12.2
	39.7	44.6	42.8	44.7	41.9	44.9	53.8	53.8	56.7	60.2	92.4	91.9
	0.2	0.3	0.3	0.6	0.4	0.4	0.3	0.4	0.4	0.4	0.3	0.4
	8.8	8.9	9.0	9.5	9.1	9.1	9.6	9.6	9.0	9.0	10.0	10.2
	52.8	52.6	52.4	76.7	59.4	57.8	69.7	93.0	87.6	66.5	113	134
	340	332	339	340	351	321	374	407	414	357	524	517
	161	115	143	90.3	134	94.9	172	118	120	116	219	187
	152	106	134	80.8	125	85.8	162	109	111	107	209	177
Profit
	158	112	138	83.0	130	94.1	165	114	113	111	215	189
	0.0	0.0	0.0	0.0	−27.3	0.0	0.0	8.0	0.0	−19.0	−26.7	0.0
	158	112	138	83.0	102	94.1	165	122	113	92.1	188	189
	40.7	29.7	34.3	21.0	31.2	25.0	45.7	27.9	31.0	27.2	60.0	49.6
	0.3	−0.9	1.0	0.3	−4.9	−0.4	0.1	3.0	−0.6	−3.3	−8.2	1.5
	41.0	28.8	35.3	21.3	26.3	24.6	45.8	30.9	30.4	23.9	51.8	51.1
	117	83.5	103	61.7	76.0	69.5	120	91.3	82.2	103	137	138
	117	83.5	103	61.7	76.0	69.5	120	91.3	82.2	68.2	137	138
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	35.2	0.0	0.0
	0.0	0.0	0.0	1.7	0.0	0.0	0.0	7.2	0.0	0.0	0.0	−1.3
	117	83.5	103	63.4	76.0	69.5	120	98.5	82.2	103	137	136
Per share
	₹50.67	₹36.26	₹44.55	₹26.79	₹32.99	₹30.18	₹51.89	₹40.00	₹35.69	₹44.90	₹59.31	₹59.79
	₹50.67	₹36.26	₹44.55	₹26.79	₹32.99	₹30.18	₹51.89	₹40.00	₹35.69	₹44.90	₹59.31	₹59.79
Continuing & discontinued operations
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	47.3	0.0	0.0
	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1	0.0	0.0
Other comprehensive income — detail
	—	0.0	—	1.7	—	—	—	—	—	—	—	—
	—	—	—	2.3	—	—	—	—	—	—	—	−1.8
	—	0.0	—	0.6	—	—	—	—	—	—	—	—
	—	—	—	—	—	—	—	−9.6	—	—	—	−0.5
	—	—	—	—	—	—	—	2.4	—	—	—	—
Per share — as-filed variants
	₹50.67	₹36.26	₹44.55	₹26.79	₹32.99	₹30.18	₹51.89	₹40.00	₹35.69	₹29.62	₹59.31	₹59.79
	₹50.67	₹36.26	₹44.55	₹26.79	₹32.99	₹30.18	₹51.89	₹40.00	₹35.69	₹29.62	₹59.31	₹59.79
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹15.28	₹0.00	₹0.00
	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹0.00	₹15.28	₹0.00	₹0.00
Regulatory disclosures — filed alongside, not part of the P&L
	—	611	—	695	—	512	—	—	—	—	—	—
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	254	213	238	212	236	198	295	265	264	242	424	414
	51.6%	48.5%	50.4%	50.4%	49.5%	48.6%	55.1%	51.5%	50.4%	52.3%	57.9%	59.6%
Adjusted (ex-exceptional items) — derived
	158	112	138	83.0	130	94.1	165	114	113	111	215	189
	0.0	0.0	0.0	0.0	−27.3	0.0	0.0	8.0	0.0	−19.0	−26.7	0.0
	117	83.5	103	61.7	96.3	69.5	120	85.3	82.2	117	156	138
	₹50.67	₹36.26	₹44.55	₹26.79	₹41.79	₹30.18	₹51.89	₹37.38	₹35.69	₹51.01	₹67.72	₹59.79

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

SANOFI₹2,992.00

Sanofi India Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersSENORES INNOVACAP PGHL MOREPENLAB IOLCP SANOFICONR FDC ORCHPHARMAMcap ₹6,882 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026	Q2 FY27 30/09/2026
Revenue from Operations	693.9	732.4	463.5	524.0	514.9	535.9	406.3	475.4	419.8	472.3	437.7	491.7
Other Income	12.0	6.5	4.8	2.3	5.9	3.3	8.7	4.9	2.8	4.4	6.2	5.5
Total Income	705.9	738.9	468.3	526.3	520.8	539.2	415.0	480.3	422.6	476.7	443.9	497.2
Expenses
+ Cost of Materials Consumed	133.5	143.7	82.1	93.1	102.7	75.7	62.1	53.3	55.3	50.3	57.3	73.6
+ Purchases of Stock-in-Trade	134.6	40.8	92.5	201.8	238.5	84.1	35.6	269.8	124.5	148.2	158.9	227.4
+ Changes in Inventories	12.2	123.9	46.5	-34.9	-91.4	80.7	111.0	-83.2	28.3	35.8	9.0	-63.0
+ Employee Benefit Expense	91.9	92.4	60.2	56.7	53.8	53.8	44.9	41.9	44.7	42.8	44.6	39.7
+ Finance Costs	0.4	0.3	0.4	0.4	0.4	0.3	0.4	0.4	0.6	0.3	0.3	0.2
+ Depreciation & Amortisation	10.2	10.0	9.0	9.0	9.6	9.6	9.1	9.1	9.5	9.0	8.9	8.8
+ Other Expenses	134.3	112.7	66.5	87.6	93.0	69.7	57.8	59.4	76.7	52.4	52.6	52.8
Total Expenses	517.1	523.8	357.2	413.7	406.6	373.9	320.9	350.7	339.6	338.8	331.6	339.5
EBITDA	187.4	218.9	115.7	119.7	118.3	171.9	94.9	134.2	90.3	142.8	115.3	161.2
EBIT	177.2	208.9	106.7	110.7	108.7	162.3	85.8	125.1	80.8	133.8	106.4	152.4
Profit
PBT before Exceptional Items	188.8	215.1	111.1	112.6	114.2	165.3	94.1	129.6	83.0	137.9	112.3	157.7
+ Exceptional Items	0.0	-26.7	-19.0	0.0	8.0	0.0	0.0	-27.3	0.0	0.0	0.0	0.0
Pretax Income	188.8	188.4	92.1	112.6	122.2	165.3	94.1	102.3	83.0	137.9	112.3	157.7
+ Current Tax	49.6	60.0	27.2	31.0	27.9	45.7	25.0	31.2	21.0	34.3	29.7	40.7
+ Deferred Tax	1.5	-8.2	-3.3	-0.6	3.0	0.1	-0.4	-4.9	0.3	1.0	-0.9	0.3
Tax Expense	51.1	51.8	23.9	30.4	30.9	45.8	24.6	26.3	21.3	35.3	28.8	41.0
Net Income	137.7	136.6	103.4	82.2	91.3	119.5	69.5	76.0	61.7	102.6	83.5	116.7
+ Net Income — Continuing Ops	137.7	136.6	68.2	82.2	91.3	119.5	69.5	76.0	61.7	102.6	83.5	116.7
+ Net Income — Discontinued Ops	0.0	0.0	35.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Other Comprehensive Income	-1.3	0.0	0.0	0.0	7.2	0.0	0.0	0.0	1.7	0.0	0.0	0.0
Total Comprehensive Income	136.4	136.6	103.4	82.2	98.5	119.5	69.5	76.0	63.4	102.6	83.5	116.7
Per Share
Basic EPS	59.79	59.31	44.90	35.69	40.00	51.89	30.18	32.99	26.79	44.55	36.26	50.67
Diluted EPS	59.79	59.31	44.90	35.69	40.00	51.89	30.18	32.99	26.79	44.55	36.26	50.67
Continuing & Discontinued Operations
+ Discontinued Operations — before Tax	0.0	0.0	47.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Tax — Discontinued Operations	0.0	0.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	—	—	1.7	—	0.0	—
+ Items NOT to be Reclassified to P&L	-1.8	—	—	—	—	—	—	—	2.3	—	—	—
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	—	—	0.6	—	0.0	—
+ Tax on Items NOT to be Reclassified — alt tag	-0.5	—	—	—	-9.6	—	—	—	—	—	—	—
+ Tax on Items to be Reclassified — alt tag	—	—	—	—	2.4	—	—	—	—	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	59.79	59.31	29.62	35.69	40.00	51.89	30.18	32.99	26.79	44.55	36.26	50.67
Diluted EPS — Continuing Operations	59.79	59.31	29.62	35.69	40.00	51.89	30.18	32.99	26.79	44.55	36.26	50.67
Basic EPS — Discontinued Operations	0.00	0.00	15.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	0.00	0.00	15.28	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period	—	—	—	—	—	—	512.2	—	695.4	—	611.0	—
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	413.6	424.0	242.4	264.0	265.1	295.4	197.6	235.5	211.7	238.0	212.5	253.7
Gross Margin %	59.61	57.89	52.30	50.39	51.49	55.12	48.63	49.54	50.43	50.39	48.55	51.60
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	188.8	215.1	111.1	112.6	114.2	165.3	94.1	129.6	83.0	137.9	112.3	157.7
− Exceptional Items (reconciliation)	0.0	-26.7	-19.0	0.0	8.0	0.0	0.0	-27.3	0.0	0.0	0.0	0.0
Net Income Adj (tax-effected)	137.7	156.0	117.5	82.2	85.3	119.5	69.5	96.3	61.7	102.6	83.5	116.7
EPS Adj	59.79	67.72	51.01	35.69	37.38	51.89	30.18	41.79	26.79	44.55	36.26	50.67
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	23.0	23.0	23.0	23.0	23.0	23.0	23.0	23.0	23.0	23.0	23.0	23.0

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q2 FY27 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Sanofi India Q2 FY27 results (July–September 2026)

Filed with NSE on Thursday, 29 October 2026 at 6:28 pm IST

Sanofi India (NSE: SANOFI) reported its Q2 FY27 results (July–September 2026) on Thursday, 29 October 2026 at 6:28 pm IST. Standalone net profit was ₹117 crore, up 53.6% from ₹76 crore in Q2 FY26 and up 39.8% from ₹83.5 crore in Q1 FY27. Revenue from operations was ₹492 crore, up 3.4% year on year and up 12.3% from the previous quarter.

Q2 FY26 results (a year earlier): 29 October 2025
Q3 FY27 results due by: 14 February 2027

Q2 FY27 at a glance · standalone

Net profit: ₹117 Cr+53.6% vs Q2 FY26+39.8% vs Q1 FY27
Revenue from operations: ₹492 Cr+3.4% vs Q2 FY26+12.3% vs Q1 FY27
Operating margin (EBIT): 31.0%+4.7 pts vs Q2 FY26+6.7 pts vs Q1 FY27EBIT ₹152 Cr
EBITDA: ₹161 Cr+20.1% vs Q2 FY26+39.8% vs Q1 FY27margin 32.8%
Earnings per share (basic): ₹50.67+53.6% vs Q2 FY26+39.7% vs Q1 FY27
Net profit margin: 23.7%+7.7 pts vs Q2 FY26+4.7 pts vs Q1 FY27

Questions

What was Sanofi India's net profit in Q2 FY27?

Standalone net profit was ₹117 crore, up 53.6% from ₹76 crore in Q2 FY26 and up 39.8% from ₹83.5 crore in Q1 FY27.

What was Sanofi India's revenue in Q2 FY27?

Revenue from operations was ₹492 crore, up 3.4% year on year and up 12.3% from the previous quarter.

What was Sanofi India's EPS in Q2 FY27?

Basic earnings per share were ₹50.67, against ₹32.99 in Q2 FY26.

How were Sanofi India's Q2 FY27 results?

Both grew from a year earlier: net profit was up 53.6% at ₹117 crore and revenue was up 3.4% at ₹492 crore. The operating margin was 31.0%, up 4.7 percentage points from 26.3% a year earlier. Against Q1 FY27, net profit was up 39.8% and revenue up 12.3%.

What was Sanofi India's operating margin in Q2 FY27?

Operating profit (EBIT — revenue less operating expenses, before finance costs and other income) was ₹152 crore, a margin of 31.0%, against 24.3% in Q1 FY27 and 26.3% in Q2 FY26. EBITDA was ₹161 crore, 32.8% of revenue.

What was Sanofi India's net profit in the first half of FY27?

Standalone net profit for the first half of FY27 (April–September 2026) was ₹200 crore, up 37.6% from ₹146 crore in the same months a year earlier. Revenue from operations was ₹929 crore, up 5.4%.

What is Sanofi India's net profit margin?

Sanofi India's net profit margin was 23.7% in Q2 FY27 (net profit as a share of revenue from operations), against 16.0% in Q2 FY26 (up 7.7 percentage points). For the year to December 2025 as a whole it was 17.8%.

How has Sanofi India's profit changed over the last four quarters?

Net profit by quarter: ₹61.7 crore in Q3 FY26, ₹103 crore in Q4 FY26, ₹83.5 crore in Q1 FY27 and ₹117 crore in Q2 FY27. That is ₹365 crore over the four quarters, up 2.3% from ₹356 crore in the four quarters before. Revenue from operations: ₹420 crore, ₹472 crore, ₹438 crore and ₹492 crore.

When did Sanofi India announce its Q2 FY27 results?

On Thursday, 29 October 2026 at 6:28 pm IST, in its results filing to the stock exchanges. A year earlier it reported Q2 FY26 on 29 October 2025.

What was Sanofi India's net profit in the year to December 2025?

Standalone net profit was ₹327 crore in the year to December 2025 (January 2024–December 2025), down 21.0% from ₹414 crore in the year to December 2024. It was ₹603 crore in the year to December 2023 and ₹621 crore in the year to December 2022: down 47.4% over three years, an average fall of 19.3% a year.

What was Sanofi India's revenue in the year to December 2025?

Revenue from operations was ₹1,837 crore in the year to December 2025 (January 2024–December 2025), down 8.7% from ₹2,013 crore in the year to December 2024. It was ₹2,851 crore in the year to December 2023 and ₹2,770 crore in the year to December 2022: down 33.7% over three years, an average fall of 12.8% a year.

When will Sanofi India announce its Q3 FY27 results?

Q3 FY27 covers October–December 2026. Listed companies must publish quarterly results within 45 days of the quarter's end (SEBI listing rules, Regulation 33), so the results are due by 14 February 2027. The company tells the exchanges the date of the board meeting at least two working days before it.

Where do these Sanofi India figures come from?

From Sanofi India's own standalone results filings to NSE, in ₹ crore as filed (Q2 FY27 on 29 October 2026). Growth compares the same standalone figures a year and a quarter earlier.

Standalone figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.